About TiGenix
TiGenix is a Healthcare company based in Leuven (Belgium) founded in 2000, and was acquired by Takeda in January 2018. Allogeneic stem cell-based therapies targeting autoimmune, inflammatory and heart diseases. TiGenix has raised $19 million across 15 funding rounds from investors including Takeda Pharmaceuticals, RA Capital and Kreos Capital. TiGenix has completed 2 acquisitions, including Cellerix and Orthomimetics. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Cell Therapy and Stem Cells.
Company details
TiGenix was established in 2000 in Leuven, Belgium, within the biotechnology sector. A proprietary platform of donor-derived expanded adipose-derived stem cells is employed to develop therapeutics. Key programs include Cx601 for perianal fistulas in Crohns disease and Cx611 for rheumatoid arthritis and sepsis. AlloCSC-01 involves allogeneic cardiac stem cells for acute ischaemic heart disease. ChondroCelect, approved for knee cartilage repair, is commercialized in Europe.
- Headquarters Leuven, Belgium
- Stage Acquired
- SectorsHealthcare
- Website tigenix.com
- Social LinkedIn
- Acquired by Takeda (Jan 2018)
- Total Equity Funding$19M (USD)
in 15 rounds
- Latest Funding Round$25.9K (USD), Post-IPO
Nov 2017
- InvestorsTakeda Pharmaceuticals
& 15 more
- Investments & AcquisitionsCellerix
& 1 more
- Acquired byTakeda
(Jan 2018)
Funding Insights of TiGenix
TiGenix has successfully raised a total of $19M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25.9 thousand completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19M
- Total Rounds 15
- Last Round Post-IPO — $25,902
- First Round $19M
(Jan 2006)
- Investors Count 15
Latest 10 of 15 funding rounds of TiGenix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2017 | $25,902 | Post-IPO | – | – | – |
| Mar 2016 | $26.09M | Post-IPO | – | – | |
| Nov 2015 | $9.25M | Post-IPO | – | – | – |
| Nov 2015 | $320,466 | Grant | – | – | |
| Dec 2013 | $13.7M | Debt – Conventional | – | – | |
| Nov 2013 | $16.18M | Post-IPO | – | – | – |
| Jul 2013 | $8.54M | Post-IPO | – | – | – |
| Dec 2012 | $8.87M | Post-IPO | – | – | – |
| Dec 2011 | Grant | – | – | – | |
| Sep 2010 | $937,000 | Grant | – | – |
16 investors in total: 16 institutional.
Investors in TiGenix
TiGenix has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, RA Capital and Kreos Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt is provided to growth-stage companies across multiple sectors. | 1998 | kreoscapital.com | London, United Kingdom | |
Brightlands Venture Partners is focused on venture capital investments. | brightlandsventurepartners.com | Geleen, Netherlands | ||
| baekelandfonds.be | ||||
Buyouts are pursued by SRIW as a private equity firm. | sriw.be | Liege, Belgium | ||
Investments are directed by Capricorn Partners into European tech ventures. | 1993 | capricorn.be | Leuven, Belgium | |
Venture capital investments are managed by Auriga Partners in France. | 1998 | aurigapartners.com | Paris, France | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
| nihr.ac.uk | ||||
Official services are provided by the Government of Flanders. | flanders.be | Belgium |
Investor details for TiGenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TiGenix
TiGenix has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cellerix and Orthomimetics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Stem Cell Therapy for the treatment of gastroenterology, dermatology, and immune-based diseases | cellerix.com | Madrid, Spain | 2004 | Feb 2011 | •••• | |
Resorbable implant for minimally invasive repair of small osteochondral defects | orthomimetics.com | Cambridge, United Kingdom | 2005 | Nov 2009 | $23.4M |
Complete acquisition details for TiGenix
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of TiGenix
7 dated milestones of TiGenix across 18 years, from founding to its latest funding, stage changes and deals.
- Founded TiGenix is founded.
- Funding First funding round of $19.0M.
- Acquisition Acquires Orthomimetics.
- Acquisition Acquires Cellerix.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $26K.
- Exit Acquired by Takeda.
Web traffic of TiGenix
Websites that share an audience with TiGenix (tigenix.com).
Websites whose visitors overlap most with TiGenix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| toxikon.com | 100% | View details | |||
| cytocell.com | 99% | View details | |||
alliancerm.org | alliancerm.org | 90% | – | ||
arthritisusa.net | arthritisusa.net | 59% | – | ||
kneecourse.com | kneecourse.com | 55% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for TiGenix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tigenix
Complete news archive for TiGenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TiGenix
TiGenix was founded in 2000 and raised its 1st funding round 6 years after it was founded.
TiGenix is headquartered in Leuven, Belgium. It is registered at Leuven, Flemish Brabant, Belgium.
TiGenix is a funded company, having raised a total of $19M across 15 funding rounds to date. The company's 1st funding round was a Grant of $937K, raised on Jan 2006.
TiGenix was established in 2000 in Leuven, Belgium, within the biotechnology sector. A proprietary platform of donor-derived expanded adipose-derived stem cells is employed to develop therapeutics. Key programs include Cx601 for perianal fistulas in Crohns disease and Cx611 for rheumatoid arthritis and sepsis. AlloCSC-01 involves allogeneic cardiac stem cells for acute ischaemic heart disease. ChondroCelect, approved for knee cartilage repair, is commercialized in Europe.
TiGenix has made 2 acquisitions, including Cellerix, and Orthomimetics.
TiGenix has 16 investors. Key investors include Takeda Pharmaceuticals, RA Capital, Kreos Capital, European Union, and Capricorn Partners.
Yes. TiGenix was acquired by Takeda in January 2018.